Pharma
Drug development platform Quris raised another $9 million, and PharmStars is accepting applications for its accelerator cohort focused on women's health and health equity.
The Drug Enforcement Administration says the digital pharmacy wrongfully distributed thousands of prescription stimulants for ADHD, including Adderall.
The companies first partnered in 2020 to develop a prescription digital therapeutic for schizophrenia. They said a treatment strategy for the condition "would benefit from a multi-product approach."
According to TechCrunch and Fierce Healthcare, the health data company also recently closed a $200 million structured equity infusion.
The collaboration will offer low-cost medications to employees and employers through a new platform dubbed EmsanaRx Plus.
The company said it will use the capital to hire for its commercial teams and advance development on new features.
The funding brings the Munich-based startup's total Series B raise to €42 million.
PointClickCare's senior health-focused datasets will help to influence Pfizer's decisions on new therapies.
The partnership will offer one platform for clinical trial sponsors, sites and participants.
The alliance will expand Sanofi's trek into tech-based drug discovery and development platforms.